Close Menu

Vela Diagnostics

The test, which runs directly from a patient nasopharyngeal swab, is the fifth assay on the firm's sample-to-result molecular diagnostics platform.

The company said that changes it made in the fourth quarter, including a recently announced restructuring plan, will lead to improvements in 2017.

The new filing comes after the firm recently withdrew plans last month to raise $8 million. 

As part of a restructuring and cost reduction plan the firm also reduced the principle of its 2016 convertible note by about half.

The PCR-based test detects Bordetella pertussis, the infectious agent that causes whooping cough, directly from patient samples. 

The firm also reported that preliminary full-year 2016 revenues improved 42 percent year over year. 

The firm has asked the SEC to withdraw a registration statement for a previously planned $8 million equity financing, saying it no longer needs the financing.

The company also increased its number of authorized shares of common stock to 1.5 billion shares from 200 million shares. 

The approval from the firm's shareholders and board comes after Great Basin moved its stock to the Over-the-Counter market in October. 

The two-hour test requires about two minutes of hands-on time to detect multiple pathogens from stool samples. 

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.